Test Price
2,800 AED✅ Home Collection Available
CFHR1 Gene Hemolytic Uremic Syndrome Genetic Test in UAE
Executive Summary & Core Metrics
Diagnostic Accuracy: 99.9% sensitivity via ISO 9001:2015 accredited next-generation sequencing for whole-gene CNV detection.
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM.
Post-Test Support: Telephonic clinical guidance from a DHA-licensed Consultant Medical Geneticist on result interpretation.
Direct Billing Inquiry: Insurance verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The CFHR1 genetic test identifies pathogenic variants in the CFHR1 gene associated with atypical hemolytic uremic syndrome (aHUS), a rare thrombotic microangiopathy that predominantly affects the kidneys. This NGS-based assay guides early diagnosis, familial risk stratification, and personalised treatment planning.
| Parameter | Our Test (NGS-CFHR1) | Closest Alternative |
|---|---|---|
| Precision | 99.9% sensitivity, whole-gene CNV detection | Limited to known hotspots (Sanger) |
| Method | Illumina NGS with advanced bioinformatics | Conventional Sanger sequencing |
| Turnaround Time | 3–4 weeks (expedited option available) | 6–8 weeks |
Physician Insight & Safety Protocols
“Genetic testing for CFHR1 variants provides families with a definitive molecular diagnosis and enables cascade screening for at-risk relatives. However, a negative result does not entirely exclude complement-mediated disease if clinical and laboratory indicators remain suggestive. The result must always be contextualised within the full clinical picture and discussed jointly with a nephrologist and a clinical geneticist.” — Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication Advisory
⚠️ Important Notice
Do not alter or stop any prescribed therapy — including eculizumab, antihypertensives, or immunosuppressants — without explicit direction from your treating physician. This genetic test provides diagnostic information only and is not a substitute for ongoing clinical management.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Patients who are haemodynamically unstable or require acute intensive care — this test is not intended for emergency triage.
- Exclusion: Individuals unable to provide informed consent for genetic testing; mandatory genetic counselling must be completed beforehand.
- Emergency Red Flag: Sudden onset of severe anaemia, oliguria or anuria, seizures, or altered mental status — seek immediate emergency care without delay for genetic results.
- Emergency Red Flag: Signs of intracranial bleeding, hypertensive crisis, or acute kidney injury necessitating dialysis.
Patient FAQ & Clinical Guidance
1. What is the CFHR1 gene test, and why is it recommended?
The CFHR1 NGS test detects genetic mutations linked to atypical hemolytic uremic syndrome, guiding diagnosis and family screening. It examines the entire CFHR1 gene for deletions, duplications, and point mutations that predispose carriers to aHUS. The test is recommended when a patient presents with thrombotic microangiopathy, low C3 levels, and no clear infectious trigger, or when there is a family history of unexplained kidney failure.
2. How is the sample collected, and what preparation is needed?
A simple blood draw or buccal swab is performed by a certified phlebotomist, requiring no fasting or medication changes. The sample can be collected at home through our VIP mobile phlebotomy service (8 AM – 11 PM) or at our partner clinics. Prior to collection, you will participate in a mandatory genetic counselling session to draw a detailed family pedigree and discuss implications. The sample (whole blood, extracted DNA, or dried blood spot on FTA card) is transported under cold-chain conditions to maintain DNA integrity.
3. What does a positive or negative result mean for my family?
A positive result confirms a CFHR1 mutation, enabling targeted family cascade testing and proactive kidney health monitoring. Carriers have an increased lifetime risk of aHUS, but not all carriers develop the disease. The result should be discussed with a nephrologist and clinical geneticist, who may recommend regular kidney function tests, complement inhibitor therapies, and avoidance of known triggers. A negative result significantly reduces the likelihood of hereditary aHUS, but does not rule out other complement-mediated disorders.
4. Will insurance cover the cost of this genetic test?
Coverage varies by insurer and policy. DNA Labs UAE offers direct billing verification through WhatsApp at +971 54 548 8731. Our team will check your eligibility and provide a pre-authorisation estimate before sample collection. Self-pay options are also available at the listed price.
5. How long does it take to get results, and how will I receive them?
The standard turnaround time is 3–4 weeks from sample receipt. Results are delivered through a secure digital portal and include a comprehensive report interpreted by our Consultant Medical Geneticist. An expedited option may be available upon request. You will also receive a telephonic post-test counselling session to review the findings and discuss next steps.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE complies fully with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is encrypted, access-controlled, and processed exclusively within the UAE. Clinical safety and patient consent protocols adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. Our ISO 9001:2015 certified laboratory operates under DHA Facility License No. 1143.
Clinical & Logistical Metadata
| Test Name | CFHR1 Gene Hemolytic Uremic Syndrome Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Whole blood, buccal swab, or dried blood spot (FTA card) |
| Methodology Used | Next-Generation Sequencing (Illumina) with CNV analysis |
| ICD-10-CM Code | D59.3 |
| LOINC Code | 81261-2 |
| DHA Facility License & Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians